A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus

ASP1941 Phase II Clinical Study - A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients With Type 2 Diabetes Mellitus

The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of ASP1941 in male and female patients with type 2 diabetes mellitus

Inclusion Criteria:

• Established diagnosis of type 2 diabetes mellitus
• Fasting serum C-peptide level > 0.6 ng/mL
• HbA1c between 7.0 and 10.0%
• Body Mass Index between 20 and 45 kg/m2

Exclusion Criteria:

• Serum creatinine > upper limit of normal
• Proteinuria (albumin/creatinine ratio > 300 mg/g)
• Dysuria and/or urinary tract infection
• Significant renal, hepatic or cardiovascular diseases
• Ketosis
• Hypertension
• Severe gastrointestinal diseases